<DOC>
	<DOCNO>NCT00135343</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy novel nucleoside spar regimen contain atazanavir , ritonavir efavirenz , use two different dos atazanavir .</brief_summary>
	<brief_title>A Pilot Study Atazanavir/Ritonavir/Efavirenz Nucleoside Sparing Regimen</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Provide write informed consent HIV positive plasma HIV RNA viral load ≥ 1000 copies/mL CD4 cell count ≥ 50 cells/mm3 Antiretroviral ( ARV ) naive prior enrollment Normal plasma triglyceride ≤ 200 mg/dL Women childbearing age must use effective barrier contraception Pregnancy breast feed Evidence resistance antiretroviral drug History elevate blood cholesterol triglycerides History diabetes Hypersensitivity component study drug Any cholesterol triglyceride lower medication past six month Use growth hormone , megestrol acetate , anabolic steroid past six month Imprisonment involuntary incarceration medical treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>HIV/AIDS</keyword>
</DOC>